New and recently funded Medical Startups
1
Country: USA | Funding: $93.9M
Adonis is a revenue intelligence and automation platform built for healthcare that improve critical RCM outcomes.
Adonis is a revenue intelligence and automation platform built for healthcare that improve critical RCM outcomes.
2
Country: USA | Funding: $60M
Thesis offers AI agents within healthcare to assist with clinical operations and care management.
Thesis offers AI agents within healthcare to assist with clinical operations and care management.
3
Country: Norway | Funding: $13.1M
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
4
Country: Italy | Funding: $220M
MMI (Medical Microinstruments) produces the world's most precise surgical robot, Symani with smallest wristed instruments. It allows surgeons to operate on lymphatic vessels smaller than 0.5 millimeters, while the physician monitors the procedure on a screen with a raised outline. The system is designed to perform microsurgical anastomoses, suture and ligate blood vessels, lymphatic ducts, and nerves, as well as for soft tissue dissection during open surgery. Symani is successfully used in neurosurgery, breast reconstruction after cancer, and lymphatic drainage procedures. MMI has also received FDA approval for clinical trials of surgical treatment for Alzheimer's disease.
MMI (Medical Microinstruments) produces the world's most precise surgical robot, Symani with smallest wristed instruments. It allows surgeons to operate on lymphatic vessels smaller than 0.5 millimeters, while the physician monitors the procedure on a screen with a raised outline. The system is designed to perform microsurgical anastomoses, suture and ligate blood vessels, lymphatic ducts, and nerves, as well as for soft tissue dissection during open surgery. Symani is successfully used in neurosurgery, breast reconstruction after cancer, and lymphatic drainage procedures. MMI has also received FDA approval for clinical trials of surgical treatment for Alzheimer's disease.
5
Country: USA | Funding: $203.1M
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
6
Country: USA
Illuminate Therapeutics is a spin-off of Pennsylvania State University developing an effective and targeted treatment for head and neck cancer that will cause minimal damage to surrounding healthy tissue. The potential treatment utilizes Illuminate's drug delivery and release platform based on light-activated nanoparticles (LADDR). It uses very focused laser to activate a light sensitive nanoparticle that delivers a nucleic acid that would target many different genes within the cancer cell. Such a precise methodology enables to use more potent chemicals to target the cancer cell.
Illuminate Therapeutics is a spin-off of Pennsylvania State University developing an effective and targeted treatment for head and neck cancer that will cause minimal damage to surrounding healthy tissue. The potential treatment utilizes Illuminate's drug delivery and release platform based on light-activated nanoparticles (LADDR). It uses very focused laser to activate a light sensitive nanoparticle that delivers a nucleic acid that would target many different genes within the cancer cell. Such a precise methodology enables to use more potent chemicals to target the cancer cell.
7
Country: UK | Funding: $77.5M
R1 Therapeutics is a clinical-stage biopharmaceutical business that develops first-in-class treatments for kidney disease patients.
R1 Therapeutics is a clinical-stage biopharmaceutical business that develops first-in-class treatments for kidney disease patients.
8
Country: USA | Funding: $5.7M
Flourish Care is a maternal healthcare center that offers childbirth education, birth plans, and newborn care services.
Flourish Care is a maternal healthcare center that offers childbirth education, birth plans, and newborn care services.
9
Country: USA | Funding: $65M
Doctronic offers an AI-powered medical assistant platform that uses a chatbot to provide medical answers and personalized health management.
Doctronic offers an AI-powered medical assistant platform that uses a chatbot to provide medical answers and personalized health management.
10
Country: USA | Funding: $155M
Qualified Health develops a platform that provides health organizations with the infrastructure to deploy and scale generative AI, including governance frameworks, post-deployment monitoring and role-based access controls. The platform also includes a risk alert system, data privacy protections designed to mitigate AI hallucinations, and a healthcare-focused AI agent creation tool to automate administrative workflows.
Qualified Health develops a platform that provides health organizations with the infrastructure to deploy and scale generative AI, including governance frameworks, post-deployment monitoring and role-based access controls. The platform also includes a risk alert system, data privacy protections designed to mitigate AI hallucinations, and a healthcare-focused AI agent creation tool to automate administrative workflows.
